Aristotle Atlantic Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Aristotle Atlantic Partners’s Portfolio OLMA Stock Details OLMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$372K	Buy	+24,953	New	+$555K	0.02%	109

Other funds holding OLMA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Aristotle Atlantic Partners's OLMA Position: Q1 2026 in Review

Aristotle Atlantic Partners opened a new position in Olema Pharmaceuticals (OLMA) in Q1 2026: 24,953 shares worth $372K. The stake represents 0.02% of the portfolio and ranks #109 among its holdings.

195 funds tracked by Wall St. Rank hold OLMA as of Q1 2026.

Aristotle Atlantic Partners held 24,953 shares of Olema Pharmaceuticals worth $372K as of Q1 2026.
Olema Pharmaceuticals was a new Aristotle Atlantic Partners position in Q1 2026.
Olema Pharmaceuticals made up 0.02% of Aristotle Atlantic Partners's portfolio in Q1 2026, its #109 holding.
195 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q1 2026.

Based on Aristotle Atlantic Partners's 13F filing for Q1 2026, filed 15 May 2026.